Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-Cell Lymphoma-Reference-Cited by-同舟云学术

Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-Cell Lymphoma

Published:2018-05 Issue:5 Volume:138 Page:1204-1206
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Rahbar Ziba,Li Shufeng,Tavallaee Mahkam,Novoa Roberto A.,Kim Jinah,Kim Youn H.

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference8 articles.

1. Multiplexed ion beam imaging of human breast tumors;Angelo;Nat Med,2014

2. Outcomes by CD30 expression in patients with CTCL receiving brentuximab vedotin (BV) vs physician’s choice (PC) in the Phase 3 ALCANZA study;Kim;J Clin Oncol,2017

3. Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: a multi-institution collaborative project;Kim;J Clin Oncol,2015

4. A guideline of selecting and reporting intraclass correlation coefficients for reliability research;Koo;J Chiropr Med,2016

5. Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brentuximab-vedotin in combination with cyclophosphamide, doxorubicin, prednisolone for the treatment of aggressive CD30-positive cutaneous T-cell lymphomas;Leukemia & Lymphoma;2023-05-31

2. Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma;The Oncologist;2022-08-10

3. Intraindividual variability of CD30 expression in mycosis fungoides –implications for diagnostic evaluation and therapy;Histopathology;2022-05-04

4. Best Practices in CD30 Immunohistochemistry Testing, Interpretation, and Reporting: An Expert Panel Consensus;Archives of Pathology & Laboratory Medicine;2022-04-26

5. What factors guide treatment selection in mycosis fungoides and Sezary syndrome?;Hematology;2021-12-10